Dihexa and IllumiNeuro Protocol Interaction: Monitor | Peptide Database

Join others researching Tretinoin — share findings, ask questions, and learn from real experiences Tretinoin is the gold standard topical retinoid for skin aging and acne, FDA-approved since 1971 for acne vulgaris and later for the treatment of photoaging (fine wrinkles, mottled hyperpigmentation, roughness). As the acid form of vitamin A, it is the most extensively studied topical anti-aging compound in dermatology, backed by decades of clinical evidence. Tretinoin accelerates epidermal cell turnover, stimulates collagen synthesis in the dermis, and improves the overall architecture of photodamaged skin. It has become a cornerstone of the biohacking and skincare optimization community due to its proven ability to reduce fine lines, even out skin tone, and improve skin texture with consistent long-term use. Tretinoin binds to retinoic acid receptors (RARs) in the cell nucleus, specifically RAR-alpha, RAR-beta, and RAR-gamma, which form heterodimers with retinoid X receptors (RXRs). These activated receptor complexes bind to retinoic acid response elements (RAREs) in DNA, modulating the transcription of genes involved in cellular differentiation, proliferation, and apoptosis. In the epidermis, tretinoin accelerates keratinocyte turnover from the typical 28-day cycle to approximately 14-16 days, promoting the shedding of damaged surface cells and their replacement with newer, healthier cells. In the dermis, tretinoin stimulates fibroblast activity, increasing the production of procollagen I and III, fibronectin, and elastin. It also inhibits matrix metalloproteinases (MMPs) that degrade collagen, and promotes angiogenesis, improving dermal blood supply. The net result is thicker, more organized epidermis, increased dermal collagen density, and reduced fine wrinkling.

Meldonium is increasingly used in the performance enhancement community as an adjunctive agent to protect the heart during anabolic steroid cycles. Supraphysiological androgen use is associated with left ventricular hypertrophy, impaired diastolic function, reduced ejection fraction, and accelerated atherosclerosis. Meldonium's ability to optimize cardiac energy metabolism and reduce toxic lipid intermediates may mitigate some of these effects, though direct clinical evidence in this specific context is limited to anecdotal and observational data. By shifting fuel utilization from fatty acids toward glucose, meldonium may improve aerobic efficiency under submaximal exercise conditions. Athletes in Eastern European countries have used meldonium for decades to support training capacity and recovery. The metabolic shift may spare glycogen during prolonged activity and reduce post-exercise oxidative stress. This use drove WADA's decision to ban the substance. In Baltic states and Russia, meldonium is an approved prescription drug for the treatment of stable angina pectoris and chronic ischemic heart disease. Clinical trials conducted primarily in Latvia and Russia have demonstrated reductions in angina frequency, improved exercise tolerance on treadmill testing, and reduced nitroglycerin consumption when meldonium is added to standard antianginal therapy. Meldonium has been investigated as an adjunctive therapy in chronic heart failure, where impaired cardiac energy metabolism contributes to disease progression. Small trials have reported improvements in exercise capacity and quality-of-life scores when meldonium was added to standard heart failure regimens. Larger-scale, Western-standard randomized controlled trials are lacking. The drug is prescribed in some Eastern European countries for acute and chronic cerebrovascular insufficiency. Its vasodilatory effects via nitric oxide stimulation and metabolic optimization may offer neuroprotective benefits during ischemic events. Evidence is primarily from non-Western clinical trials.